Literature DB >> 20972543

Current opinion: complications and troubleshooting of sacral neuromodulation.

Paul Pettit1.   

Abstract

The complications of sacral neuromodulation have been minimized as technology has improved. The main surgical complication remains to be surgical site infection. We review evidence-based suggestions and procedure-specific techniques that reduce the infection rate to less than 2%. In the past, surgical revision was reported as high as 40%. The current revision rate at Mayo Clinic Florida is 10%. The most common reason for surgical revision is either battery end-of-life or loss of effectiveness. We review the best practices of the procedure and a systematic approach to troubleshoot loss of effectiveness.

Entities:  

Mesh:

Year:  2010        PMID: 20972543     DOI: 10.1007/s00192-010-1279-x

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  11 in total

1.  Modified techniques of S3 foramen localization and lead implantation in S3 neuromodulation.

Authors:  T C Chai; G J Mamo
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

2.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study.

Authors:  Philip E V van Kerrebroeck; Anco C van Voskuilen; John P F A Heesakkers; August A B Lycklama á Nijholt; Steven Siegel; U Jonas; Clare J Fowler; Magnus Fall; Jerzy B Gajewski; Magdy M Hassouna; Francesco Cappellano; Mostafa M Elhilali; Douglas F Milam; Anurag K Das; H E Dijkema; Ubi van den Hombergh
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

Review 3.  Contemporary management of neuropathic pain for the primary care physician.

Authors:  Hsiupei Chen; Tim J Lamer; Richard H Rho; Kenneth A Marshall; B Todd Sitzman; Salim M Ghazi; Randall P Brewer
Journal:  Mayo Clin Proc       Date:  2004-12       Impact factor: 7.616

4.  Predictors of success for first stage neuromodulation: motor versus sensory response.

Authors:  Brian L Cohen; Hari S G R Tunuguntla; Angelo Gousse
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

5.  Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation.

Authors:  Jonathan S Starkman; Christopher E Wolter; Harriette M Scarpero; Douglas F Milam; Roger R Dmochowski
Journal:  Neurourol Urodyn       Date:  2007       Impact factor: 2.696

6.  Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?

Authors:  Cindy L Amundsen; Audrey A Romero; Margaret G Jamison; George D Webster
Journal:  Urology       Date:  2005-10       Impact factor: 2.649

Review 7.  Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety.

Authors:  Michele Spinelli; Karl-Dietrich Sievert
Journal:  Eur Urol       Date:  2008-02-08       Impact factor: 20.096

8.  Evaluation and management of malfunctioning sacral neuromodulator.

Authors:  Darlene M Gaynor-Krupnick; Neil T Dwyer; Helen Rittenmeyer; Karl J Kreder
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

9.  Re-operation rates after permanent sacral nerve stimulation for refractory voiding dysfunction in women.

Authors:  Roberta E Blandon; John B Gebhart; Deborah J Lightner; Christopher J Klingele
Journal:  BJU Int       Date:  2008-01-10       Impact factor: 5.588

Review 10.  Topical negative pressure for treating chronic wounds.

Authors:  Dirk T Ubbink; Stijn Joël Westerbos; Debra Evans; Lucy Land; Hester Vermeulen
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16
View more
  2 in total

Review 1.  Specific Tips for General Controversies in Sacral Neuromodulation.

Authors:  Ahmed S El-Azab; Steven W Siegel
Journal:  Curr Urol Rep       Date:  2016-11       Impact factor: 3.092

Review 2.  Troubleshooting Interstim Sacral Neuromodulation Generators to Recover Function.

Authors:  C R Powell
Journal:  Curr Urol Rep       Date:  2018-08-20       Impact factor: 3.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.